Anti-Fibrogenic Effects of Captopril and Candesartan Cilexetil on the Hepatic Fibrosis Development in Rat

Experimental and Toxicologic Pathology - Germany
doi 10.1078/0940-2993-00309
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Biorelevant Dissolution of Candesartan Cilexetil

ADMET and DMPK
PharmacologyHealthMedicineToxicologyChemistryPharmaceutics
2017English

Update on the Clinical Pharmacology of Candesartan Cilexetil

American Journal of Hypertension
Internal Medicine
2000English

Development of Orodispersible Tablets of Candesartan Cilexetil-Β-Cyclodextrin Complex

Journal of Pharmaceutics
2013English

Effects of Candesartan Cilexetil on Urinary Protein Excretion in Patients With Essential Hypertension.

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
2011English

Evaluation of the Pharmacokinetic Interaction Between Candesartan Cilexetil and Felodipine

Journal of Bioequivalence & Bioavailability
2011English

Reduction of Bleomycin Induced Lung Fibrosis by Candesartan Cilexetil, an Angiotensin II Type 1 Receptor Antagonist

Thorax
PulmonaryRespiratory Medicine
2004English

Candesartan Cilexetil/Hydrochlorothiazide Combination Treatment Versus High-Dose Candesartan Cilexetil Monotherapy in Patients With Mild to Moderate Cardiovascular Risk (CHILI Triple T)

Vascular Health and Risk Management
2011English

Relative Antihypertensive and Glomeruloprotective Efficacies of Enalapril and Candesartan Cilexetil in the Remnant Kidney Model

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Internal MedicineEndocrinology
2001English

Inhibitory Effect of Candesartan Cilexetil on Left Ventricular Remodeling After Myocardial Infarction

International Heart Journal
MedicineCardiovascular MedicineCardiology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy